| Coronavirus RNA proofreading: molecular basis and therapeutic targeting F Robson, KS Khan, TK Le, C Paris, S Demirbag, P Barfuss, P Rocchi, ... Molecular cell 79 (5), 710-727, 2020 | 447 | 2020 |
| Zip Nucleic Acids: new high affinity oligonucleotides as potent primers for PCR and reverse transcription V Moreau, E Voirin, C Paris, M Kotera, M Nothisen, JS Remy, JP Behr, ... Nucleic acids research 37 (19), e130-e130, 2009 | 96 | 2009 |
| Zip nucleic acids are potent hydrolysis probes for quantitative PCR C Paris, V Moreau, G Deglane, E Voirin, P Erbacher, N Lenne-Samuel Nucleic acids research 38 (7), e95-e95, 2010 | 49 | 2010 |
| Nucleic acid-based technologies targeting coronaviruses TK Le, C Paris, KS Khan, F Robson, WL Ng, P Rocchi Trends in Biochemical Sciences 46 (5), 351-365, 2021 | 46 | 2021 |
| Antisense oligonucleotides, a novel developing targeting therapy S Karaki, C Paris, P Rocchi Antisense Therapy 10, 2019 | 33 | 2019 |
| Exploiting protected maleimides to modify oligonucleotides, peptides and peptide nucleic acids C Paris, O Brun, E Pedroso, A Grandas Molecules 20 (4), 6389-6408, 2015 | 26 | 2015 |
| Enhanced antisense oligonucleotide delivery using cationic liposomes grafted with trastuzumab: A proof-of-concept study in prostate cancer G Sicard, C Paris, S Giacometti, A Rodallec, J Ciccolini, P Rocchi, ... Pharmaceutics 12 (12), 1166, 2020 | 22 | 2020 |
| Conjugating phosphospermines to siRNAs for improved stability in serum, intracellular delivery and RNAi-Mediated gene silencing C Paris, V Moreau, G Deglane, L Karim, B Couturier, ME Bonnet, ... Molecular pharmaceutics 9 (12), 3464-3475, 2012 | 20 | 2012 |
| Structure− Activity Relationship of a Series of Inhibitors of Monoacylglycerol Hydrolysis Comparison with Effects upon Fatty Acid Amide Hydrolase JA Cisneros, S Vandevoorde, S Ortega-Gutiérrez, C Paris, CJ Fowler, ... Journal of medicinal chemistry 50 (20), 5012-5023, 2007 | 18 | 2007 |
| DDX5 mRNA-targeting antisense oligonucleotide as a new promising therapeutic in combating castration-resistant prostate cancer TK Le, C Cherif, K Omabe, C Paris, F Lannes, S Audebert, E Baudelet, ... Molecular Therapy 31 (2), 471-486, 2023 | 14 | 2023 |
| Rational design of novel N-alkyl-N capped biostable RNA nanostructures for efficient long-term inhibition of gene expression M Terrazas, I Ivani, N Villegas, C Paris, C Salvans, I Brun-Heath, ... Nucleic Acids Research 44 (9), 4354-4367, 2016 | 13 | 2016 |
| Menin inhibition suppresses castration-resistant prostate cancer and enhances chemosensitivity C Cherif, DT Nguyen, C Paris, TK Le, T Sefiane, N Carbuccia, P Finetti, ... Oncogene 41 (1), 125-137, 2022 | 12 | 2022 |
| Nanovectorization of prostate cancer treatment strategies: a new approach to improved outcomes K Omabe, C Paris, F Lannes, D Taïeb, P Rocchi Pharmaceutics 13 (5), 591, 2021 | 11 | 2021 |
| Antisense oligonucleotide-based therapeutic against menin for triple-negative breast cancer treatment DT Nguyen, TK Le, C Paris, C Cherif, S Audebert, S Oluchi Udu-Ituma, ... Biomedicines 9 (7), 795, 2021 | 6 | 2021 |
| Nucleoside-lipid-based nanoparticles for phenazine delivery: a new therapeutic strategy to disrupt Hsp27-eIF4E interaction in castration resistant prostate cancer H Ziouziou, C Paris, S Benizri, TK Le, C Andrieu, DT Nguyen, A Appavoo, ... Pharmaceutics 13 (5), 623, 2021 | 4 | 2021 |
| ZNF703 mRNA-Targeting Antisense Oligonucleotide Blocks Cell Proliferation and Induces Apoptosis in Breast Cancer Cell Lines S Udu-Ituma, J Adélaïde, TK Le, K Omabe, P Finetti, C Paris, A Guille, ... Pharmaceutics 15 (7), 1930, 2023 | 1 | 2023 |
| Chemical modification patterns for microRNA therapeutic mimics: a structure-activity relationship (SAR) case-study on miR-200c M Garreau, J Weidner, R Hamilton, E Kolosionek, N Toki, K Stavenhagen, ... Nucleic Acids Research, gkae141, 2024 | | 2024 |
| Antisense oligonucleotides and their use for the treatment of cancer P Rocchi, LE Thi-Khanh, F BERTUCCI, D Taieb, C PARIS, P Finetti | | 2021 |
| Nanovectorization of Prostate Cancer Treatment Strategies: A New Approach to Improved Outcomes. Pharmaceutics 2021, 13, 591 K Omabe, C Paris, F Lannes, D Taïeb, P Rocchi s Note: MDPI stays neutral with regard to jurisdictional claims in published …, 2021 | | 2021 |
| DDX5, une nouvelle cible thérapeutique dans le cancer de prostate résistant à la castration F Lannes, K Le Thi, C Cherif, S Benizri, L Fazli, C Paris, M Gleave, ... Progrès en Urologie 29 (13), 700-701, 2019 | | 2019 |
